Previous Close | 8.98 |
Open | 8.97 |
Bid | 9.00 x 800 |
Ask | 9.01 x 1100 |
Day's Range | 8.96 - 9.06 |
52 Week Range | 8.29 - 15.90 |
Volume | |
Avg. Volume | 890,267 |
Market Cap | 8.685B |
Beta (5Y Monthly) | 0.21 |
PE Ratio (TTM) | 16.46 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jun 03, 2021 |
1y Target Est | N/A |
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and the development of innovative diagnostic solutions, today announced that its Procleix Plasmodium Assay has obtained the CE mark, the first for an automated nucleic acid test (NAT) system specifically validated for screening blood donors for malaria.
SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs. The article demonstrates the potential of GigaGen’s machine learning
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced that the presentations from the May 10th and 11th Depositary Receipts Virtual Investor Conference (“dbVIC”) are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, Hong Kong, Germany, Portugal, South Africa, Spain and the UK presented their equity stories and